The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection
Open accessAbstract
Background & aims There is substantial interest in liquid biopsy approaches for cancer early detection among subjects at risk, using multi-marker panels. CA19-9 is an established circulating biomarker for pancreatic cancer; however, its relevance for pancreatic cancer early detection or for monitoring subjects at risk has not been established.Methods CA19-9 levels were assessed in blinded sera from 175 subjects collected up to 5 years before diagnosis of pancreatic cancer and from 875 matched controls from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. For comparison of performance, CA19-9 was assayed in blinded independent sets of samples collected at diagnosis from 129 subjects with resectable pancreatic cancer and 275 controls (100 healthy subjects; 50 with chronic pancreatitis; and 125 with noncancerous pancreatic cysts). The complementary value of 2 additional protein markers, TIMP1 and LRG1, was determined.Results In the PLCO cohort, levels of CA19-9 increased exponentially starting at 2 years before diagnosis with sensitivities reaching 60% at 99% specificity within 0 to 6 months before diagnosis for all cases and 50% at 99% specificity for cases diagnosed with early-stage disease. Performance was comparable for distinguishing newly diagnosed cases with resectable pancreatic cancer from healthy controls (64% sensitivity at 99% specificity). Comparison of resectable pancreatic cancer cases to subjects with chronic pancreatitis yielded 46% sensitivity at 99% specificity and for subjects with noncancerous cysts, 30% sensitivity at 99% specificity. For prediagnostic cases below cutoff value for CA19-9, the combination with LRG1 and TIMP1 yielded an increment of 13.2% in sensitivity at 99% specificity (P = .031) in identifying cases diagnosed within 1 year of blood collection.Conclusion CA19-9 can serve as an anchor marker for pancreatic cancer early detection applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CA19–9 elevations can be observed in plasma samples obtained in the pre-diagnostic setting, suggesting a potential window of opportunity for early detection38.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783
Self-citationInternational consensus guidelines 2012 for the management of IPMN and MCN of the pancreas
Tanaka, M., Fernández-del Castillo, C., Adsay, V., Chari, S., Falconi, M., Jang, J.-Y., Kimura, W., Levy, P., Pitman, M. B., Schmidt, C. M., et al. (2012) · Pancreatology · doi:10.1016/j.pan.2012.04.004 · Cited by 2,354
Self-citationRyan, D. P., Hong, T. S., & Bardeesy, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1404198 · Cited by 2,348
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
Liu, M. C., Oxnard, G. R., Klein, E. A., Swanton, C., Seiden, M. V., Liu, M. C., Oxnard, G. R., Klein, E. A., Smith, D., Richards, D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.011 · Cited by 1,495
Self-citation
Cited by
Sorted by citations
Items 201–208 of 208
Семёнов, Н. Н., Зарьянов, Д. А., & Feoktistova, P. S. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-228
Wang, X., Yang, H., Li, J., Wang, X., Tong, L., Han, Z., Li, Y., Liu, M., Guo, L., Zhou, S., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1903036
Liquid Biopsy and Multi‐Cancer Early Detection Tests for Cancer Screening: A Scoping Review
Robinson, T., Saab, M., Nguyen, L. T., Kochar, P., Meggetto, O., Tinmouth, J., & Walker, M. J. (2026) · Clinical Genetics · doi:10.1111/cge.70249
Abe, T., Takikawa, T., Kikuta, K., Matsumoto, R., Tanaka, Y., Sano, T., Hayashi, H., Sekino, Y., Tanaka, Y., Masuo, T., et al. (2026) · Pancreatology · doi:10.1016/j.pan.2026.10.007
Artificial Intelligence in Pancreatic Cancer: From Predictive Performance to Clinical Translation
Khan, I., Belhaj, A., Gemini, A., Ibis, K. A., Darsif, N., Rouani, N., Vanlander, A., & Messaoudi, N. (2026) · Cancers · doi:10.3390/cancers18203253
Ngufor, C. G., Patel, S., Weston, A. D., Bogdanski, A. M., Wijsman, K. J. H., Li, J., Wallace, M. B., & Bi, Y. (2026) · Research Square · doi:10.21203/rs.3.rs-11265358/v1
Liang, T., Ao, Y., Sun, H., Zhang, C., Wang, Y., & Zhang, M. (2026) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2026.09.021
Strategies and tools for enhancing early detection of pancreatic cancer
Liao, W. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.10.024
Metadata
- Authors
- Fahrmann, J. F., Schmidt, C. M., Mao, X., Irajizad, E., Loftus, M., Zhang, J., Patel, N., Vykoukal, J., Dennison, J. B., Long, J. P., Do, K.-A., Zhang, J., Chabot, J. A., Kluger, M. D., Kastrinos, F., Brais, L., Babic, A., Jajoo, K., Lee, L. S., Clancy, T. E., Ng, K., Bullock, A., Genkinger, J., Yip-Schneider, M. T., Maitra, A., Wolpin, B. M., & Hanash, S.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Indiana University School of Medicine (US)
- Harvard University (US)
- Columbia University Irving Medical Center (US)
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Hanash, Samir
- ORCID
- Fahrmann, Johannes F.
- Schmidt, C. Max
- Mao, Xiangying
- Irajizad, Ehsan
- Loftus, Maureen
- Zhang, Jinming
- Dennison, Jennifer B.
- Long, James P.
- Do, Kim-Anh
- Zhang, Jianjun
- Kluger, Michael D.
- Kastrinos, Fay
- Brais, Lauren
- Lee, Linda S.
- Clancy, Thomas E.
- Ng, Kimmie
- Bullock, Andrea
- Genkinger, Jeanine
- Yip-Schneider, Michele T.
- Maitra, Anirban
- Wolpin, Brian M.
- Hanash, Samir
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 160
- Issue
- 4
- Pages
- 1373-1383.e6
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC8783758
- OpenAlex
- W3110895646
- Cited by
- 208
- References
- 56
- Citations by year
- 2026: 37 · 2025: 52 · 2024: 40 · 2023: 37 · 2022: 30 · 2021: 12
- FWCI
- 7.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute
- Pancreatic Cancer Action Network
- Lustgarten Foundation
- University of Texas MD Anderson Cancer Center
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- CA19-9, pancreatic cancer, early detection, liquid biopsy, circulating tumor markers, TIMP-1, LRG1, multimarker panels, pre-diagnostic biomarkers, chronic pancreatitis, pancreatic cysts, PLCO Cancer Screening Trial
- MeSH terms
- Liquid Biopsy, Aged, Diagnosis, Differential, Feasibility Studies, Female, Humans, Male, Mass Screening, Middle Aged, Pancreatic Cyst, Pancreatic Neoplasms, Sensitivity and Specificity, United States, CA-19-9 Antigen, Pancreatitis, Chronic, Early Detection of Cancer, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
